{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:07:30Z","timestamp":1795036050580,"version":"4.10.2"},"reference-count":21,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic cell transplantation (HCT) and autologous hematopoietic stem cell\u2013based gene therapies are potentially curative for sickle cell disease (SCD). Although most patients experience resolution of overt clinical symptoms associated with SCD with donor-dominant myeloid chimerism after undergoing HCT or the induction of a substantial amount of alternative hemoglobin (Hb) after gene therapy (GT), whether the underlying subclinical physiology is normalized in these individuals is unknown. One approach to evaluating the underlying physiology is to characterize the blood rheology of patients after they receive these therapies. We assessed the rheology of 123 blood samples from 69 patients, of whom 43 underwent HCT (32 from matched related donors; 11 from haploidentical donors) and 11 received GT. The results were compared to those for patients treated with hydroxyurea with optimum fetal Hb response (HUOptimum; n = 15). Median rheology parameters of recipients of HCT from donors with sickle cell trait (HbAS) were superior to those of GT recipients (elongation index under hypoxia [EImin]: 0.6 vs 0.31; point of sickling [PoS]: 0 vs 26.21) and of the HUOptimum cohort (EImin, 0.6 vs 0.15; PoS, 0 vs 36.2; percentage of dense red blood cells, 0.9 vs 4.9; P&amp;lt;\u2009.05 for all comparisons). Results for the GT and HUOptimum groups were comparable (P&amp;gt;\u2009.05). Given the substantial number of patients with abnormal rheology and the associations between rheology and SCD-related complications, rheology tests may be included in the follow-up care for HCT and GT recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020768","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:56:37Z","timestamp":1784073397000},"page":"6170-6177","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Blood rheology after allogeneic hematopoietic stem cell transplantation or gene therapy in sickle cell disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0075-3304","authenticated-orcid":false,"given":"Ashwin P.","family":"Patel","sequence":"first","affiliation":[{"name":"1Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Children\u2019s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-3559","authenticated-orcid":false,"given":"Tami D.","family":"John","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Stanford Medicine Children\u2019s Health, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[{"name":"3Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8220-9980","authenticated-orcid":false,"given":"Brandon M.","family":"Triplett","sequence":"additional","affiliation":[{"name":"3Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"De Vita","sequence":"additional","affiliation":[{"name":"4Novartis Biomedical Research, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1386-6685","authenticated-orcid":false,"given":"Elizabeth O.","family":"Stenger","sequence":"additional","affiliation":[{"name":"1Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Children\u2019s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[{"name":"3Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-2255","authenticated-orcid":false,"given":"Vivien A.","family":"Sheehan","sequence":"additional","affiliation":[{"name":"1Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Children\u2019s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"3","key":"2026092210521679900_bib1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.27164","article-title":"Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing","volume":"99","author":"Locatelli","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"2026092210521679900_bib2","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.bbmt.2018.04.002","article-title":"Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the second Pediatric Blood and Marrow Transplant Consortium international conference on late effects after pediatric HCT","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2026092210521679900_bib3","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood.2024024519","article-title":"How I treat sickle cell disease with gene therapy","volume":"144","author":"Sharma","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026092210521679900_bib4","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2026092210521679900_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MOH.0000000000000786","article-title":"Mixed donor chimerism following stem cell transplantation for sickle cell disease","volume":"30","author":"Shah","year":"2023","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"2026092210521679900_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia","volume":"7","author":"Walters","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"2026092210521679900_bib7","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026092210521679900_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"2026092210521679900_bib9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2026092210521679900_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"2026092210521679900_bib11","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2026092210521679900_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1535370219900494","article-title":"Blood rheology biomarkers in sickle cell disease","volume":"245","author":"Lu","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"2026092210521679900_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/bloodadvances.2023011013","article-title":"Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease","volume":"8","author":"Rab","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026092210521679900_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.19006","article-title":"Association of haemolysis markers, blood viscosity and microcirculation function with organ damage in sickle cell disease in sub-Saharan Africa (the BIOCADRE study)","volume":"203","author":"Ranque","year":"2023","journal-title":"Br J Haematol"},{"issue":"2-3","key":"2026092210521679900_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/CH-189005","article-title":"Blood rheological abnormalities in sickle cell anemia","volume":"68","author":"Connes","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"issue":"15","key":"2026092210521679900_bib16","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/bloodadvances.2024015590","article-title":"Use of the microfluidic impedance red cell assay (MIRCA) in sickle cell disease","volume":"9","author":"Patwardhan","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026092210521679900_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/hematology.2022000373","article-title":"Long-term health outcomes following curative therapies for sickle cell disease","volume":"2022","author":"Chakravarthy","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"2026092210521679900_bib18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/17474086.2024.2423368","article-title":"Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management","volume":"17","author":"Goldenberg","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"2026092210521679900_bib19","author":"Biswas","year":"2018"},{"issue":"7","key":"2026092210521679900_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2026092210521679900_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/bloodadvances.2022008137","article-title":"Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease","volume":"7","author":"Leonard","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6170\/2588265\/blooda_adv-2026-020768-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6170\/2588265\/blooda_adv-2026-020768-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:23Z","timestamp":1790088743000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6170\/569709\/Blood-rheology-after-allogeneic-hematopoietic-stem"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":21,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020768","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,10]]}}}